Aurinia Pharmaceuticals (AUPH) Share-based Compensation (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of Share-based Compensation data on file, last reported at -$866000.0 in Q1 2026.

• Quarterly Share-based Compensation fell 109.69% year-over-year to -$866000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (down 86.07% YoY) and the FY2025 annual result came in at $14.7 million, down 53.54% from the prior year.
• Share-based Compensation declined to -$866000.0 in Q1 2026, from $6.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $25.7 million in Q4 2024 to a low of -$31.3 million in Q4 2023.
• A 5-year average of $3.2 million and a median of $6.7 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation plunged 383.99% — and 2024, when it jumped 182.22%.
• Tracing AUPH's Share-based Compensation over 5 years: stood at -$24.4 million in 2022, then dropped by 28.35% to -$31.3 million in 2023, then jumped by 182.22% to $25.7 million in 2024, then tumbled by 73.83% to $6.7 million in 2025, then plunged by 112.87% to -$866000.0 in 2026.
• The last three Share-based Compensation figures came in at -$866000.0 (Q1 2026), $6.7 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.